A Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sara M TolaneyShanu Modi

Abstract

DLYE5953A is an antibody-drug conjugate consisting of an anti-LY6E antibody covalently linked to the cytotoxic agent monomethyl auristatin E. This study characterized the safety, pharmacokinetics, immunogenicity, potential biomarkers, and anti-tumor activity of DLYE5953A in patients with metastatic solid tumors. This was a phase I, open-label, 3+3 dose-escalation, and dose expansion study of DLYE5953A administered intravenously every 21 days (Q3W) in patients with locally advanced or metastatic solid malignancies. Sixty-eight patients received DLYE5953A (median: 4 cycles; range: 1-27). No dose limiting toxicities were identified during dose escalation (0.2-2.4 mg/kg; n=20). The recommended phase II dose (RP2D) of 2.4 mg/kg Q3W was based on overall safety and tolerability. Dose expansion cohorts for HER2-negative metastatic breast cancer (HER2-negative MBC) (n=23) and non-small cell lung cancer (NSCLC) (n=25) patients were enrolled at the RP2D. Among patients receiving DLYE5953A 2.4 mg/kg (n=55), the most common (>=30%) related adverse events (AEs) included alopecia, fatigue, nausea, and peripheral neuropathy. Grade >=3 related AEs occurred in 14/55 (26%) of patients, with neutropenia being the most common (13%). DLYE5953A demon...Continue Reading

References

Sep 11, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Angelo de ClaroRichard Pazdur
Sep 17, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xuan XuJianqing Xu
Nov 29, 2014·Journal of Medicinal Chemistry·Andreas MadernaChristopher J O'Donnell
Apr 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shang-Fan YuAndrew G Polson
Apr 12, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jyoti AsundiRon Firestein
Sep 18, 2017·Journal of Pharmacokinetics and Pharmacodynamics·Matts KågedalChunze Li
Apr 28, 2015·Toxics·Roser Velasco, Jordi Bruna
Jun 19, 2019·Bioanalysis·Montserrat Carrasco-TrigueroSurinder Kaur
Sep 22, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David E GerberHoward A Burris
Nov 7, 2019·Viruses·Jingyou Yu, Shan-Lu Liu
Nov 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C DanilaHoward I Scher

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.